Finck Amanda V, Blanchard Tatiana, Roselle Christopher P, Golinelli Giulia, June Carl H
Center for Cellular Immunotherapies, Perelman School of Medicine, and Parker Institute for Cancer Immunotherapy at University of Pennsylvania, Philadelphia, PA, USA.
Immunology Graduate Group, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Nat Med. 2022 Apr;28(4):678-689. doi: 10.1038/s41591-022-01765-8. Epub 2022 Apr 19.
This year marks the tenth anniversary of cell therapy with chimeric antigen receptor (CAR)-modified T cells for refractory leukemia. The widespread commercial approval of genetically engineered T cells for a variety of blood cancers offers hope for patients with other types of cancer, and the convergence of human genome engineering and cell therapy technology holds great potential for generation of a new class of cellular therapeutics. In this Review, we discuss the goals of cellular immunotherapy in cancer, key challenges facing the field and exciting strategies that are emerging to overcome these obstacles. Finally, we outline how developments in the cancer field are paving the way for cellular immunotherapeutics in other diseases.
今年是嵌合抗原受体（CAR）修饰的T细胞用于难治性白血病细胞治疗的十周年。基因工程改造的T细胞在多种血癌中获得广泛的商业批准，为其他类型癌症患者带来了希望，而人类基因组工程与细胞治疗技术的融合为新一代细胞疗法的产生具有巨大潜力。在本综述中，我们讨论了癌症细胞免疫治疗的目标、该领域面临的关键挑战以及为克服这些障碍而出现的令人振奋的策略。最后，我们概述了癌症领域的进展如何为其他疾病的细胞免疫治疗铺平道路。
